Ara
Toplam kayıt 1, listelenen: 1-1
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
(Mattioli 1885, 2023)
Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ...